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The design and execution of prevention trials for OA have methodological issues that are distinct from
trials designed to impact prevalent disease. Disease deﬁnitions and their precise and sensitive
measurement, identiﬁcation of high-risk populations, the nature of the intervention (pharmaceutical,
nutraceutical, behavioral) and its potential pleiotropic impacts on other organ systems are critical to
consider. Because prevention trials may be prolonged, close attention to concomitant life changes and co-
morbidities, adherence and participant retention in the trial is of primary importance, as is recognition of
the potential for “preventive misconception” and “behavioral disinhibition” to affect the ability of the
trial to show an effect of the intervention under study. None of these potential pitfalls precludes
a successful and scientiﬁcally rigorous process and outcome. As technology improves the means to
measure and predict the OA process and its clinical consequences, it will be increasingly possible to
screen individuals for high-risk phenotypes, combining clinical factors with information from imaging,
genetic, metabolic and other biomarkers and to impact this high-risk condition to avoid or delay OA both
structurally and symptomatically.
 2011 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Osteoarthritis (OA) is the most common speciﬁc arthritis
condition, affecting 27 million people in the United States in 20051.
Knee and hip OA are generally considered to have the greatest
impact due to effects on ambulation2. OA of these joints accounted
for 97% of the total knee replacements and 8% of the total hip.M. Jordan, Thurston Arthritis
Hill, NC 27599-7280, USA.
. Jordan).
Elsevier Ltd on behalf of Osteoartreplacements for arthritis in 20043. OA, however, is frequently
a generalized condition, involvingmultiple joint sites, including the
hand, knee, hip, great toe, and spine, all of which can be associated
with signiﬁcant symptoms and disability4e6.
In 2007, the Osteoarthritis Research Society International (OARSI)
was awarded a contract from the Federal Drug Administration (FDA)
to review issues related to the design and conduct of clinical trials for
OA, particularly pertaining to agents purporting to effect disease
modiﬁcation (See Introduction to Issue). Several categories ofhritis Research Society International.
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including Imaging, Biomarkers, Deﬁnition of Disease State, Safety,
and Prevention and Risk Reduction. This paper will discuss the
outcome of deliberations by the Working Group for Prevention and
Risk Reduction. This Working Group was composed of individuals
from academia and the pharmaceutical industry. The remit of this
group was to examine potential outcome measures, the desirable
duration of, and population for, an OA prevention trial, and the safety
database and acceptable risk that would be required for prevention.
Lastly, a research agenda to inform these issues was requested.
Through a series of face-to-face meetings, telephone conferences,
and electronic mail exchanges over almost 2 years, the members of
the Working Group discussed these relevant questions, reviewed
literature as required to inform answers, and presented the ﬁnal
product to a public forum attended by representatives from the FDA,
the OARSI, and the National Institutes of Health (NIH), and academic
and industry/private foundation communities.
Generally, clinical trials in OA have addressed three major types
of outcomes: (1) symptoms of pain, function, and stiffness; (2)
structural disease progression; and (3) replacement of affected
joints. The clinical trials in OA to relieve symptoms of pain or
stiffness and to improve function may involve pharmaceutical
or nutraceutical agents7, devices (i.e., braces, shoe orthotics), or
behavioral interventions, such as weight-reduction, exercise, or
increased physical activity8e12. The less common disease-modi-
fying trials aim to demonstrate slowing of the rate of structural
progression, (frequently measured by change in joint space nar-
rowing on radiographs of the knee or hip13e15) and have employed
pharmaceuticals or neutraceutical with, for example, putative
anti-oxidant properties, the ability to inhibit cartilage degradative
enzymes, impact bone turnover, modulate inﬂammation, or
enhance or induce cartilage repair and/or lubrication16,17. The goal
of these trials is to prevent structural progression of established
disease, or to prevent disability or the need for total joint replace-
ment, an indicator of total joint failure, in those with established
disease, ie tertiary prevention. A third major type of OA trial
involves evaluation of actions intended to assure the safety, efﬁ-
ciency, and efﬁcacy of joint replacement.
This report will address the primary and secondary prevention
and risk reduction of structural and symptomatic indicators of OA.
These types of trials face speciﬁc hurdles because the onset of OA
can be insidious and progression slow, with consequently, the need
for trials of long duration, or the use of proxy measures with
imperfect sensitivity and speciﬁcity for development of OA clinical
outcomes, to allow the trial to be feasible. This report will discuss
deﬁnitions, eligible populations and high-risk groups to whom
initial prevention efforts might be directed for proof of concept, and
possible outcome/surrogate outcome measures for primary and
secondary prevention and risk reduction (Fig. 1). Then, an exampleFig. 1. Structural abn’l¼ structural abnormality.of a prevention and a risk reduction trial for knee OA, directed at the
high-risk group of those who are overweight or obese, and young
athletes at risk of knee injury, respectively, will be proposed. These
example trial designs are directed at knee OA with the under-
standing that OA in other joint sites (i.e., hands and hip) may have
different prevalences, different risk factor proﬁles, different natural
history of development and unique measures to deﬁne the disease
state. Therefore, the approaches in these examples may not be
generalizable to OA affecting joints other than the knee. In these
examples, the recommended duration of a trial and appropriate
database for safety will be outlined. Finally, ethical issues
surrounding the conduct of clinical trials for OA prevention will be
introduced.
Deﬁnitions of prevention and risk reduction
For the purposes of this report, prevention refers to those agents
or actions that curtail or delay the onset or new occurrence of
clinically diagnosed OA at the joint site of interest, in someone
initially without evidence satisfying the clinical deﬁnition of the
condition. Components of this deﬁnition may include structural
evidence, e.g., on radiographs, and characteristic signs and symp-
toms, e.g., bony enlargement, crepitus, and/or pain. This report will
not address tertiary prevention, or treatment, to modify the
progression of established disease or achieve the maximum
accommodation of living with established disease. Risk reduction
refers to decreasing speciﬁc and modiﬁable risk factors associated
with the development of OA, in an attempt to decrease the likeli-
hood of developing OA or to delay its onset. For example, since
obesity and overweight are strong risk factors for knee OA, aweight
loss intervention could be evaluated to determine its ability to
reduce the risk of developing knee OA in the obese. Similarly, since
joint trauma, with its frequently resultant altered biomechanics, is
a strong risk factor for the development of OA, an intervention to
alter abnormal biomechanics in those with joint injury could also
be considered in a preventive context for OA. Further, an inter-
vention to prevent joint injury in the ﬁrst place would be an
example of risk reduction. It must also be acknowledged that an
intervention may be both a preventive measure and a risk reduc-
tion measure, i.e., a weight loss intervention would ﬁt both cate-
gories though the outcomes would differ (incident OA vs loss of
weight).
Because the presentation of OA is frequently generalized, i.e.,
occurs in more than one joint in more than one joint group, an
intervention could be applied in someone with OA in one joint site,
in order to prevent the development of OA in another joint site
unaffected at the start of the trial. For example, those with hand OA
could be the subject of a prevention trial to prevent the develop-
ment of OA in the knees or hips6. This situation blurs the distinction
between incidence of new disease and progression of established
disease, and may need to be considered on a case-by-case basis,
with statistical methodology applied to allow for the non-inde-
pendence of multiple joints within the same person. This also
suggests that collection of information about joints beyond the
target joint should be considered at the beginning and throughout
the trial, both for the purpose of recognizing important secondary
effects of the intervention and for identifying potential safety
signals of the intervention.
Study populations
In a prevention trial, the optimal study population to demon-
strate efﬁcacy most efﬁciently would be at high risk for future OA,
but free of full evidence satisfying an accepted and operational
disease deﬁnition. However, the initial testing of an intervention on
Fig. 2. Three-year transition probabilities of KeL score of 1 (doubtful OA) staying at a
KeL¼ 1 or progressing to a KeL¼ 2 to OA as a function of age (years) and BMI (kg/m2):
designing a prevention trial of knee OA. (A) Transition probability of KeL¼ 1 score
staying at KeL¼ 1; (B) Transition probability of KeL¼ 1 score to a KeL¼ 2 score,
indicative of OA.
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generalizability, necessitating further testing on others with
varying degrees of risk. Or, the efﬁcacy of agents which might be
effective in those of lower risk, but prove ineffective in the “high-
risk” population, would remain undiscovered. Ultimately, the study
population selection cannot be dictated and is dependent upon the
deﬁnition of disease that is employed and overall goals of the trial.
A prevention trial study population can be selected to represent
the three major domains of disease deﬁnition related to OA: (1)
structural compromise, (2) pain and other symptoms, and (3)
impaired function. Additionally, physiological/immunological/
genetic locally or systemicallymeasuredbiomarkers, such as synovial
ﬂuid aggrecan, serumC-reactive protein (CRP) or cartilage oligomeric
matrix protein (COMP), urinary type II collagen telopeptides (uCTX-
II), or combinations of biomarkers, might be incorporated to either
deﬁne an at-risk population or to exclude individuals from selection
into a prevention trial18. Further, population selection can be predi-
cated on addressing each of these domains singularly or in combi-
nation19. For discussion of the current state of qualiﬁcation of
biomarkers for OA, the reader is referred to the article in this issue on
Biomarkers.
Eligible study populations for trials to prevent
structurally-deﬁned OA
If the eligible population for a prevention trial is to be free of
structurally-deﬁned OA, one option for deﬁning a “disease-free”
population includes enrollment of persons with Kell-
greneLawrence (KeL) radiographic grades 0 or 1. Decision-
making based on the selection of a population with a KeL score of
KeL¼ 0 vs KeL¼ 1, which is designated as “doubtful OA” must
acknowledge that there is an embedded probability that indi-
viduals with a KeL¼ 1 have early OA20, or the underlying
conditions leading to OA, but have not yet been identiﬁed
deﬁnitively radiographically. This probability should be factored
into estimating the sample size and developing data analytic
strategies. Similar concepts apply if the study population lacks
knee OA, deﬁned as the absence of a deﬁnite osteophyte.
Currently, there are very limited data organized to inform these
design issues; this is the rationale for this report including a call
to identify and organize data to support making evidence-based
design choices.
An example of the type of data needed comes from the 15-year
study of the natural history of knee OA development (the Michigan
Bone Health and Metabolism Study) encompassing 660 women
who were aged 24e44 at the 1992 study inception. The women
were recruited from a population-based sample to increase the
likelihood of generalizability of the ﬁndings. Radiographs, taken
every 3 years, were scored by two radiologists using KeL deﬁni-
tions for OA knee severity.
The probability of moving from one KeL score to the same or
a different KeL score in a 3-year period was estimated using
Markov transition modeling. Estimating the probabilities of tran-
sitioning from a KeL score of 1 (proposed here as an example for
a prevention trial) to other KeL scores reveals the impact of age and
body mass index (BMI) and provides evidence to deﬁne inclusion
and exclusion criteria in the prevention trial.
At age 50, the probability that a KeL¼ 1 score would remain at
a KeL¼ 1 score 3 years later was 54e59% when BMIs ranged from
25 kg/m2 to 35 kg/m2 [Fig. 2(A)]. The probability of transitioning
from KeL¼ 1 score to KeL¼ 2 score in a 3-year period ranged from
8% in non-obese women to 15% in women with a BMI 35 kg/m2
[Fig. 2(B)]. The probability of transitioning from a KeL¼ 1 score to
a KeL¼ 3 score in a 3-year period is less than 2% (data not shown
graphically). This evidence-based approach increases the likelihoodof having efﬁciently designed trials of prevention practices to
forestall the development of knee OA.
Efforts are underway to deﬁne structural changes of knee OA by
techniques other than the standing knee radiograph. For instance,
static magnetic resonance imaging (MRI) to deﬁne OA based on
morphologic changes in cartilage, bone or other soft tissues21 or
functional magnetic resonance imaging (fMRI) or other types of MRI
measures (such as delayed gadolinium-enhanced MRI of cartilage
[dGEMRIC], T2-mapping, T1rho, sodium imaging, etc) to deﬁne OA
based on compositional changes in cartilage, bone or other soft
tissues22,23 may become modalities of choice. Currently, there is no
agreed upon deﬁnition of OA based on these technologies. However,
the ﬁeld is rapidly evolving, i.e., the OARSI FDA Initiative Imaging
WorkingGroup is currently developing criteria for the early diagnosis
of kneeOAusingMRI, and thesedevelopmentsmust beanticipated in
developing future trials (See article on Imaging in this issue).Eligible study populations for trials to prevent symptoms of OA
If the eligible population lacks characteristic deﬁning symptoms,
especially pain or stiffness, the limits of allowable symptomsmust be
carefully deﬁned, includinghowpain is to beassessed, its severityand
duration, and the allowable frequency for transient pain, and poten-
tially whether or not pain in joints apart from the target joints are
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such as analgesics or non-steroidal anti-inﬂammatory drugs
(NSAIDs), also needs to be factored into themethodologic strategy to
assess symptoms of OA24. Depending upon the mode of action of the
agent under study, it may be necessary to disallow some usual or
rescue medications to decipher the effect of the intervention unam-
biguously. For example, if the mechanism of action of the agent to be
used effects pain relief through disruption of bone turnover, it might
be necessary to exclude the use of drugs that affect bone turnover,
such as bisphosphonates. If a drug is related to narcotics, it might be
necessary to exclude the use of narcotics as rescuemedication. Again,
these issues, critical to the design of prevention trials, cannot be
dictated and must be decided in the context of the trial under
consideration.
Eligible study populations for trials to prevent functional decline
from OA
If the eligible study population is to be free of functional perfor-
mance impediments, investigators will need to determine whether
inclusion criteria are based on self-report instruments or perfor-
mance-based assessments. There are numerous questionnaire-based
instruments to characterize functional status (See article on Func-
tional status measures in this issue). For the selection of a study
population, it is particularly important to choose an instrument or
combination of instruments that have a known speciﬁcity (the
knownprobability of truly being free of functional compromise), and
that speciﬁcity should be relevant to the population fromwhich the
prevention trial population will be recruited. The use of perfor-
mance-based assessment in prevention trial recruitment is limited
by the relative absence of normative data in persons younger than
age 65, thereby precluding the ability to estimate the probability of
any speciﬁc assessment value’s actually representing the disease-
free state for a prevention trial. Further, there aremany determinants
of function which may or may not be directly relevant to OA. Alter-
natively, these measures may be considered to be estimates of an
“at-risk” state and therefore eligible for study in a prevention trial; it
is important that the predictive capacity of these performance
measures over a period of time for increased compromise be known.
Use of biomarkers to deﬁne eligible study populations for prevention
trials in OA
If the eligible study population will be selected based on
physiological or immunological biomarker measures, there are at
least two expectations. First, there must be adequate information
to discern when a speciﬁc value of the biomarker(s) truly repre-
sents a “disease-free” state and, second, information about the
rapidity of the biomarker change (if treated as a continuous vari-
able) or conversion (if treated as a discrete variable) in relation to
the development of disease, must be known and available. Addi-
tionally, the biomarker must have been previously validated
against a clinically relevant endpoint for its use as a surrogate
measure25. Even if the biomarker is used only as a criterion for
inclusion or exclusion for participation in a prevention trial, it must
have sufﬁcient evidence of predictive relevance to warrant its
application. Further discussion of this topic is found in the article
on Biomarkers.
High-risk groups to target for prevention and risk reduction
For primary prevention and risk reduction, careful character-
ization of the relevant risk factor of interest is as critical as being
able to deﬁne the absence of OA. It is important to be able to (1)
deﬁne and measure the risk factor unambiguously, and (2) knowthe relative contribution of the risk factor to OA disease develop-
ment, the average duration to disease manifestation among those
with and without the risk factor, and the prevalence of the risk
factor in the population. Clinical risk factors for OAmay be joint-site
speciﬁc, i.e., rupture of the anterior cruciate ligament (ACL) as a risk
factor for the development of knee OA. Other risk factors may exert
systemic effects on risk of OA in multiple joints. The latter situation
includes factors such as age, female gender, overweight and obesity,
endocrine disorders, and family history or genetically-deﬁned
population subgroups. Although not all of these are modiﬁable,
they may inﬂuence participant selection criteria in certain trials.
As our measurement tools become increasingly sensitive and
precise, it may be possible to classify the risk status of individuals
and groups based on characteristics such as cartilage lesions on
MRI, levels of biomarkers associated with OA development, or
possession of a speciﬁc genotype.
Sample trial design for prevention of knee OA in overweight
and obese
- The following is presented for illustrative purposes only, and
should NOT be considered a prescriptive mandate for the
design of a prevention trial. Further, as deﬁnitions of at risk
populations change and measurements of the disease process
and outcomes advance, it is expected that design features of
such a trial would necessarily evolve as well. It is critical to
enrich the probability of including individuals who may
develop knee OA in a shorter and feasible time frame that
acknowledges that clinical trials of long duration are not only
costly, but are difﬁcult to implement (i.e., to conduct an
interventionwithout drift or maintain a study group compliant
with the protocol, etc.). Including persons with an increased
likelihood of developing disease will improve the ability to
determine the intervention’s effectiveness in preventing
disease, but may limit generalizability.
Proposed study population
The study population for a primary or secondary prevention trial
should be structured to the proposed intervention. A reasonable
“high-risk” study population for a prevention trial could consist of
ambulatory, community-dwelling men and women aged 50e65
years with: (1) no more than a “questionable” osteophyte (KeL¼ 1)
in the medial or lateral tibiofemoral compartment (2) knee varus or
valgus malalignment (angle 2 and 10); (3) BMI 30 kg/m2
and 45 kg/m2; (4) sedentary lifestyle, i.e., no participation within
the past 6 months in an exercise program that incorporated more
than 30min/week of formal exercise; and, (5) the absence of inter-
view-determined knee pain or limited function for a month-long
time period. Scores on either questionnaire-based or performance-
based functional assessment will reﬂect values considered in the
“normal” range for men and women in the 50e65 year age range. A
detailed record ofmedication use should be collected at baseline and
for each speciﬁc follow-up testing interval.
Rationale for criteria
- Use of KeL¼ 1 rather than KeL¼ 0, 1 should increase the
likelihood that individuals will develop OA20.
- A 30< BMI< 45 kg/m2 is likely to include a population that is
obesebut able to participate in adesignated intervention, and for
which normative measures are interpretable. The range of BMI
should be evaluated for population groups of shorter stature,
such as ﬁrst generation Asian enrollees to BMI of 25e35 kg/m2.
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considered for exclusion because of the difﬁculty in using
computerized tomography and MRI equipment to characterize
hard and soft tissue structures. Additionally, in this group, there
is a lower exercise compliance rate associated with high BMIs26.
- Including only those with moderate malalignment (varus or
valgus knee angle 2 and 10) will potentially allow more
rapid development of disease, because medial and lateral knee
OA progression is strongly associated with moderate malalign-
ment, and this may or may not be independent of body size27.
However, this is not absolute, since data supporting the role of
malalignment in the development of new knee OA is
controversial28,29.
Possible interventions
Interventions could be pharmacologic or non-pharmacologic.
Importantly, an intervention in a primary or secondary prevention
trial has unique elements in that (1) implementation is likely, but
not deﬁnitely, to require a protracted administration period; (2)
the administration cannot generate risk of accentuating other
potential on-going disease processes; and (3) a careful weighing of
the costs and beneﬁts must occur. For example, bariatric surgery
might be considered a candidate intervention for a primary
prevention trial for OA, but its use imposes unique consideration
for other heath costs and risks of morbidity and mortality. One
way to address this issue could be to append an ancillary study for
prevention of knee OA to an on-going trial of bariatric surgery for
other outcomes. An active drug (unknown at this point) could be
directed toward decreasing inﬂammation and/or pain or
improving weight management. A functional intervention might
include measures to modify alignment and/or build strength. A
behavioral intervention could be directed toward increasing
physical activity, changing the type of physical activity, or modi-
fying dietary practices.
It is also possible that a preventive intervention might not have
to be administered over prolonged periods of time. Such a situation
might obtain in the setting of acute joint injury, in which hypo-
thetical Agent X might be injected into the injured joint weekly for
4 weeks. Assessment of such a regimen could improve the feasi-
bility and tolerability of delivering the intervention itself, but would
not eliminate the need for prolonged assessments to ascertain
whether the agent inhibited the onset of OA and whether it is safe.
Primary outcomes
If the trial hypothesis is that an intervention in a prevention trial
among obese adults with no or doubtful evidence of radiographic
knee OA (KeL¼ 0,1) will be associatedwith a delayed onset of knee
OA compared to the placebo group, this delay could be reﬂected in
two co-primary outcomes: less symptom report and minimal
structural change in relation to the untreated group. Candidate
measures to detect these areas include changes in: (1) KeL score or
minimal joint space and (2) questionnaire-based pain assessment.
Other potentially relevant outcome measures could include newer
technologies once they have been validated, such as MRI with or
without T2-mapping to assess morphological changes in joint
structures or articular cartilage degradation and/or bone marrow
lesions. As imaging and molecular techniques advance to the stage
where they could be surrogates of downstream clinical outcomes, it
may be that an intervention might be able to show a primary effect
on structure of the OA process, regardless of its immediate effect on
symptoms. While examples of prevention in other medical condi-
tions abound, e.g., interventions directed toward lowering serum
cholesterol or altering lipid proﬁles to prevent futurecardiovascular events30,31, or altering bone mineral density to
prevent osteoporotic fractures32, it is unlikely that requirements for
a proposed intervention to affect relevant clinical outcomes would
be waived entirely.
Secondary outcomes
Secondary outcomes could include some or all of the following
largely predicated on the nature of the proposed intervention:
(1) clinical measures of function, pain andmobility; (2) mechanistic
measures of the OA disease pathways such as knee alignment, knee
external adductor moment, knee joint compressive and shear
forces, and; (3) biomarker measures of pro-inﬂammatory mole-
cules (e.g., interleukin-6 (IL-6), Tumor Necrosis Factor-a, CRP) and
joint metabolism (e.g., uCTX-II, COMP); (4) lower extremity
strength and power; (5) limb proprioception; and (6) abdominal
and thigh fat depots measured by CT; (7) adverse effects associated
with the intervention; and (8) quality of life.
In addition to OA outcome measures, investigators need to
select or develop appropriate measures of intervention-related
processes and adherence to the intervention.
Study time line
Depending upon the factors discussed above, a primary
prevention trial is likely to require a 10-year follow-up with data
collected from participants at 1 or 2-year intervals. The interval
distance should be based on time required to detect meaningful
differences in the measures of interest and motivate subjects to
maintain optimal participation in the trial. For example, MRI, knee
X-ray, gait, and strength might be measured biannually (years 2, 4,
6, 8, and 10), while biomarker levels might be assessed every 3e6
months. Proposed trials of shorter duration, with proper justiﬁca-
tion of clinically relevant outcomes and safety monitoring, would
likely improve feasibility.
Sample trial design for prevention of knee OA by preventing
knee injury
Many of the issues above also apply to trials of injury prevention,
but the latter have a number of unique, key design features worthy
of separate discussion and illustrated by a trial of an educational/
exercise intervention vs an attention control to prevent knee injury
in high school female basketball players. This is an example of a risk
reduction trial to prevent injury that might later lead to knee OA.
Selecting a sample/population
Injury prevention trialsmust identify populations at considerable
risk of the relevant injury. Low risk populations are inefﬁcient to
study because event rates are minimal, requiring very large samples
or longer trial duration, which may lead to contamination across
study arms and considerable attrition of study participants. Sports
teams,military trainees and other such groups exposed to high levels
of demanding physical activity are appropriate at-risk populations.
Unit of randomization
Such prevention studies often require cluster-randomized
designs, in which the unit of randomization is the group, not the
individual subject. These may include sports teams, schools, sports
leagues, or even towns. For the trial of female basketball players, the
cluster group is the high school team. The rationale for randomizing
at the group level is to reduce contamination, or diffusion of the
intervention to the control group. For example, if two basketball
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player randomized to receive exercises may show the exercises to
the player in the control group. Cluster randomization reduces this
risk. Furthermore, cluster randomization permits the group to be
incorporated into the intervention. When an entire school is
randomized to an educational intervention arm, the investigators
can display injury prevention educational posters in the school and
not worry about contamination. Cluster-randomized designs are
typically costly in terms of sample size because each observation is
not independent. The more similar the outcomes are among
members of the group, and the larger the cluster group, the greater
the sample size needed to overcome the non-independence.
Intervention protocol
Interventions in injury prevention trials must be delivered in
a standardized fashion at all intervention sites. This requires
training, reliability assessment, site visits, and logistical work to
ensure that the intervention is administered similarly across
diverse settings. In this example, a basketball injury prevention
program allocated at the school level needs to be delivered iden-
tically despite differences in the gyms, practice schedules and
coaches’ styles in different schools.
Outcome assessment
Assessments must be done in a standardized fashion at regular
intervals using well-deﬁned, reproducible outcome deﬁnitions. In
many trials the outcome is injury, but investigatorsmust clarify what
constitutes an injury (a sore knee for an hour? a day? with swelling,
deﬁned by whom? had to leave practice or game? had to miss next
game? radiographic or imaging ﬁndings, e.g., ligamentous injury,
meniscal injury, fracture?). This assessment should ideally be made
by an observer blinded to random intervention assignment.
Statistical analysis
The analysis of cluster-randomized intervention trials must use
techniques (such as generalized estimating equations) that account
for clustered observations33 or risk artiﬁcially lowering variance
estimates and over-stating the statistical signiﬁcance.
Methodological considerations for prevention trials
Study design
As these examples illustrate, the double blinded, randomized,
placebo or active comparator study design is the gold standard, but its
appropriateness is dependent upon the agent and the availability of
known effective interventions for primary preventions. Many likely
interventions may be difﬁcult or impossible to blind completely.
Further, many potential primary prevention interventions, such as
the injury prevention trial, may be more effectively delivered using
cluster randomization, where the community is the unit of analysis,
rather than the individual33. In this case, contamination related to
community behavioral or other change can inﬂuence results and
must be rigorously addressed34. Therefore, selection of study design
for the trialwill bedependent upon intervention, thedegree towhich
individual implementation is feasible, and the capacity to include an
effective placebo.
Adherence
It is a particular problem for long-term interventions, particu-
larly if participants do not readily perceive beneﬁt from continuedparticipation or experience other barriers. Both the active inter-
vention and placebo groups will require supplemental behavioral
components to maintain adherence, and the inclusion of an
adherence specialist on the study team may be wise.
There are also organic factors that may inﬂuence adherence. It
may be appropriate to assess for depression symptoms and design
interventions and intervention monitoring to address their impact
in terms of both individual behaviors as well as interactions of
depression therapy with the intervention for OA. Female enrollees
are likely to be in the midst of the menopause transition and the
degree of symptoms and stage of the transition are likely to inﬂu-
ence both behaviors and potentially structural tissue responses.
This suggests that adherence management needs to be prepared to
deal with concomitant symptomatic conditions and potential
interventions associated with those symptoms. The proposed age
range is likely to reﬂect other competing illness processes that may
affect adherence, as well as directly impact intervention effective-
ness and potential for side-effects.Recruitment
It is the life-blood of any clinical trial; however, recruiting for
a primary prevention trial imposes requirements that are not
always evident in treatment trials. Recruitment could be enhanced
by using complementary strategies coupled with a system that
provides feedback on each strategy’s effectiveness and cost35. Mass
mailings and media (newspaper, television, internet) may be
effective in some settings. Depending upon the age of the primary
prevention target population, having strong ties with local aging
service networks and access to senior centers, churches, drug
stores, shopping malls, and other sites where older adults gather
could be important but may be ineffective for the population
50e65 years. Most health science centers maintain a large database
of adults who have signed consent to be contacted about partici-
pating in future clinical trials; however, it is important to identify
why these adults are associated with such registries and if their
registration is associated with diseases that may impinge on the
intervention or decrease the likelihood that they are going to be
free of OA.
Experience has proven that on-goingmonitoring of the recruitment
process is necessary to achieve study goals and to review recruitment
activities, plan new activities, and monitor the number of contacts24.
Close attention should be given to the gender and minority
frequencies of those who qualify for, and enroll in, the study.Safety database for trials of prevention of OA
Because a prevention trial for OA could involve an intervention
with active agents administered to otherwise healthy individuals, or
to individuals with co-morbid conditions, for extended periods of
time, the safety database must be extensive and involve information
frommultiple organ systems. The extent of this safety database may
depend upon the intervention. For example, systemically-adminis-
tered interventions may have pleiotropic effects, e.g., statins or
bisphosphonates36e39, reinforcing the need to monitor multiple
organ systems for toxicity. A more localized intervention, such as an
unloading brace, might not require the same degree of vigilance for
safety in remote organ systems. Observations must also be long in
duration, particularly for agents that might impact the immune
system and be associated with infections or subsequent develop-
ment of cancer. Finally, when trials are of considerable duration, such
as in these cases of OA prevention, careful monitoring of evolving
technology that might impact the long-term assessment of outcome
must also occur. See article on Safety as part of this issue.
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As recently reviewed40, rheumatology clinical trials may involve
some issues that pose speciﬁc ethical concerns. This may particu-
larly be the case in prevention trials for OA. First, since currently no
clearly effective agents exist, novel agents to be used in primary
prevention must ﬁrst include substantial testing on healthy
volunteers or people with early disease to establish viability.
Prevention trials necessarily involve people who may not have the
disease in question, who may not ever get the disease, or who
might experience a relatively benign course even with no inter-
vention. Further, for a condition such as OA, which develops over
years, any effective agent for prevention would likely need to be
administered for a prolonged time, possibly beginning at an early
age. The potential for multi-system toxicity must be monitored,
especially in younger individuals who may be of reproductive age
when the agent is started.
Some preventive interventions may be directed at the pop-
ulation level, rather than provide beneﬁt to a speciﬁc individual.
An example of this would be a vaccine study. In this instance,
studying a treatment in a person with disease can be profoundly
different than studying an intervention in healthy people. Studies
in other diseases have shown that study participants may have
misconceptions about the potential effectiveness of a preventive
intervention and/or may have inﬂated estimates of the likelihood
that they will be randomized to get the active agent, and may have
exaggerated impressions of the likelihood that the intervention
will be personally effective for them. Simon and colleagues have
called this the “preventive misconception,” deﬁned as “the over-
estimate in probability or level of personal protection that is
afforded by being enrolled in a trial of a preventive interven-
tion”41. This can be particularly problematic when accompanied
by “behavioral disinhibition” or the adoption of behaviors that
may pose a risk to the participant or others. This has been
observed in persons participating in a HIV vaccine trial, in which
individuals had an increase in risky behaviors41. In the case of OA,
various scenarios could be imagined, in which behavioral disin-
hibition could occur. One could imagine that someone with
a strong family history of OA, or even someone who possessed
a very high-risk genotype, might be less vigilant about main-
taining a normal weight because of a false expectation that the
preventive agent he/she received in a trial will be effective and
protect him/her from his/her increased risk of OA. These issues
emphasize the critical importance of the informed consent
process in OA trials, particularly those for prevention.
Recommendations for future research
First and foremost is the requirement that research continue to
work to reﬁne deﬁnitions of OA, utilizing genetic, biochemical, and
imaging biomarkers and psychometrically valid questionnaires and
performancemeasures,with the goal of diminishing ambiguity in the
currently used metrics and increasing their clinical relevance.
Collection of extensive biological specimens, e.g., serum, plasma,
DNA, RNA, urine, should be a part of all of these on-going and future
studies.
Observational studies with both short and long-term follow-up
can be particularly helpful in this regard, to deﬁne molecular, struc-
tural and symptomatic correlates of disease and to identify risk
factors predictive of the development of disease and its clinical
impact. Attention to gender and minority inclusion, with the requi-
site consideration of distinct issues regarding their propensity to
participate in prevention trials, should be a part of this research
agenda. Observational studies can be particularly helpful in the
following activities: Evaluation of existing datasets with particularly long follow-up
times (10, 20 ormore years) in order to identify risk factors that
may be exposed long in advance of disease onset.
 Extended follow-up as adults of cohorts established during
childhood, adolescence, and early adulthood, for the develop-
ment of OA.
 Extended, detailed follow-up of inception cohorts of thosewith
acute joint injury, with detailed information regarding the
events and treatmentmodalities applied in the acute setting, as
well as other potential risk factors.
 Evaluation of existing datasets with detailed genetic, biomarker,
and imaging data to expand our information about various OA
phenotypes along the continuum from molecular to pre-radio-
graphic OA, to radiographic to symptomatic OA.
 Addition of short follow-up times (i.e., months), to studies of
existing cohorts to obtain sensitive, dynamic imaging and other
biomarker data to aid prediction of the development of struc-
tural and clinical disease.
 Evaluation of distinct ethnic/racial sub-populations to ascer-
tain accurate assessment of the burden of disease in these
groups, differences in risk factor proﬁles, and genetic, imaging,
and biomarker sub-types in order to tailor trials to relevant
groups, (i.e., differences in BMI that might be used to screen
Asians or African Americans into prevention trials for the
overweight/obese).
 Methodological studies of distinct threats to validity of
prevention trials and their execution, related to cultural differ-
ences in attitudes toward trial participation and risk factor
reduction; techniques to maximize adherence and retention;
and ways to measure and overcome biases such as preventive
misconception and behavioral disinhibition. As one example,
the use of technology, such as hand-held devices and the
Internet, for participant recruitment, retention and data collec-
tion, is becoming more widespread and will continue to evolve.
The study of the impact of such methods upon prevention trials
in general will likely inform future prevention trials for OA.
An additional future direction may be a multi-center clinical
trial of a non-pharmacologic intervention, alone and in combi-
nation with a pharmacologic co-therapy, that can alter mecha-
nisms in the pathological pathway (e.g., decrease knee joint
loading and reduce inﬂammation) to OA and thus lower its inci-
dence. The 2009 NIAMS Roundtable presented a roadmap for how
prevention trials should be organized. For large multi-center
trials, NIAMS will identify the most qualiﬁed investigators who
will be required to ﬁrst establish the need for a larger trial with
results from a planning grant or similar study. This will allow
applicants to demonstrate their abilities to design and manage
clinical trials before launching a full-scale project. The large-scale
project should be comprehensive, incorporating clinical (e.g.,
pain, function), mechanistic (e.g., inﬂammation and knee joint
loading), and structural (e.g., quantitative cartilage morphology
with qMRI, semi-quantitative whole joint scoring) outcomes.
Demonstrating the ability to identify and target people who are at
high-risk of OA will be crucial as this will lay the foundation for
primary prevention efforts.
Secondary prevention is equally important. Knee trauma, such as
ACL or meniscus injury, is a strong predictor of subsequent knee OA.
Considering the young age at which many of these injuries occur,
knee joint replacement at a relatively young age is a distinct possi-
bility, possibly followedby a second replacement after 10e15 years. A
secondary prevention trial with outcomes related to the risk of knee
replacement would have important public health implications. Knee
and hip strengthening in young adults with knee trauma to reduce
the risk of knee replacement would be an example of a secondary
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the location listed below.
 (http://www.niams.nih.gov/news_and_events/Meetings_and_
Events/Roundtables/2009/ortho_OA.asp).
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